All In Biotech

Drug Trial Radar · NCT02783729

Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Parallel-Group Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)

Last checked: Nov 19, 2026Latest source record: Nov 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,006 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,006

Actual

Start

May 31, 2016

Primary completion

Jan 30, 2018

Study completion Jan 30, 2018

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
First posted
May 26, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will be conducted to demonstrate, using polysomnography, that lemborexant 10 milligrams (mg) and 5 mg is superior to placebo on objective sleep onset as assessed by latency to persistent to sleep (LPS) after the last 2 nights of 1 month of treatment in participants 55 years and older with insomnia disorder.

Conditions

  • Insomnia

Interventions

  • LemborexantDrug

    Lemborexant 5 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.

  • LemborexantDrug

    Lemborexant 10 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.

  • Lemborexant-matched placeboDrug

    Lemborexant-matched placebo be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.

  • Zolpidem tartrateDrug

    Zolpidem tartrate extended release 6.25 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.

  • Zolpidem-matched placeboDrug

    Zolpidem-matched placebo will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Mean Latency to Persistent Sleep (LPS) of Lemborexant 10 mg and Lemborexant 5 mg Compared to Placebo on Days 29/30Time frame: Baseline, Days 29/30

Locations

102 sites in 7 countries. Site status is shown where the registry gives one.

  • Jasper Summit Research LLC

    Jasper, Alabama

  • PACT

    Glendale, Arizona

  • Preferred Research Partners

    Little Rock, Arkansas

  • Site not named

    Carlsbad, California

  • Southern California Research

    Fountain Valley, California

  • Pacific Sleep Medicine Services

    Oceanside, California

  • Research Center of Southern California

    Oceanside, California

  • Orange County Neuropsychiatric Research Center, LLC

    Orange, California

  • SDS Clinical Trials, Inc.

    Orange, California

  • Artemis Institute For Clinical Research LLC

    San Diego, California

  • Pacific Research Network Inc

    San Diego, California

  • Artemis Institute For Clinical Research

    San Marcos, California

  • Santa Monica Clinical Trials

    Santa Monica, California

  • Empire Clinical Research

    Upland, California

  • PAB Clinical Research

    Brandon, Florida

  • Saint Francis Sleep Allergy and Lung Institute

    Clearwater, Florida

  • Fleming Island Center For Clinical Research

    Fleming Island, Florida

  • Sarkis Clinical Trials

    Gainesville, Florida

  • MD Clinical

    Hallandale, Florida

  • QPS MRA

    Hollywood, Florida

  • Quest Pharmaceutical Services-Miami Research Associates, LLC (QPS MRA)

    Miami, Florida

  • Research Centers of America

    Oakland Park, Florida

  • Compass Research LLC

    Orlando, Florida

  • NeuroMedical Research Institute

    Panama City, Florida

  • Clinical Research Group of St Petersburg Inc

    St. Petersburg, Florida

  • NeuroTrials Research Inc.

    Atlanta, Georgia

  • SleepCare Research Institute Inc

    Stockbridge, Georgia

  • Northwestern University

    Chicago, Illinois

  • Chicago Research Center Inc

    Chicago, Illinois

  • Helene A Emsellem MD PC

    Chevy Chase, Maryland

  • Sleep Disorders Center of the Mid-Atlantic

    Glen Burnie, Maryland

  • Neurocare Inc

    Newton, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Henry Ford Hospital

    Novi, Michigan

  • Clinical Neurophysiology Services

    Sterling Heights, Michigan

  • St. Louis Clinical Trials

    St Louis, Missouri

  • Clayton Sleep Institute

    St Louis, Missouri

  • Clinical Research Center of Nevada

    Las Vegas, Nevada

  • Hassman Research Institute

    Berlin, New Jersey

  • CLINiLABS, Inc.

    Eatontown, New Jersey

Showing 40 of 102 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.